Audited Standalone and Consolidated Financial Results for the quarter and year ended 31-03-2025
3BBLACKBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
3B BlackBio Dx Ltd reported strong FY25 results with consolidated revenue from operations growing about 30% to ₹9,646.86 lakhs (from ₹7,412.47 lakhs in FY24). Consolidated profit after tax rose nearly 49% to ₹4,769.11 lakhs (from ₹3,210.12 lakhs), and EPS jumped to ₹55.65 from ₹37.46. On a standalone basis, revenue grew about 28% to ₹9,052.97 lakhs and PAT rose around 39% to ₹4,755.95 lakhs. The Diagnostic Kits segment is the key growth driver, contributing ₹8,428.25 lakhs of segment revenue versus ₹1,278.61 lakhs from Agrochemicals. Operating cash flow remained healthy at ₹3,779.18 lakhs (consolidated) and cash & equivalents stood at ₹6,843.22 lakhs. The Board recommended a final dividend of ₹4 per share (40%) for FY25, subject to shareholder approval. Statutory auditor Baheti & Co. issued an unqualified opinion on both standalone and consolidated results.
Strong double-digit revenue and profit growth, robust cash generation, and a healthy 40% dividend signal solid financial health and shareholder-friendly policy — likely to be viewed positively by investors.